ABSTRACT
Several reports have demonstrated that bovine chromosome 26 (BTA26) harbours significant or suggestive quantitative trait loci (QTL) for milk production and composition traits in dairy cattle. Our previous study showed that a C/T substitution in the bovine TCF7L2 gene on BTA26 was significantly linked to QTL for protein yield (PY) in a Canadian dairy cattle population. Actually, this polymorphism was one of the markers derived from a genome-wide screening of QTL for milk PY using an amplified fragment length polymorphism technique combined with a DNA pooling strategy. In the present study, 990 Holstein bulls with complete genotype and phenotype data from 14 sire families were analysed to confirm, if the QTL effects exist in other populations. Statistical analysis revealed that this marker was significantly associated with PY, protein percentage, milk yield and fat yield (FY) (p < 0.001) in the US Holstein population. These results indicate that this QTL region has a pleiotrophic effecton different milk traits and is portable in different populations.
Subject(s)
Cattle/genetics , Lactation/genetics , Milk/chemistry , Milk/metabolism , Quantitative Trait Loci , TCF Transcription Factors/genetics , Analysis of Variance , Animals , Cattle/physiology , DNA/chemistry , Gene Frequency , Genotype , Polymerase Chain Reaction/veterinary , TCF Transcription Factors/physiology , Transcription Factor 7-Like 2 ProteinABSTRACT
The critical care nurse caring for the postoperative bleeding patient must have a thorough knowledge of basic hemostatic principles and inherited and acquired disorders. Early recognition and treatment of bleeding problems reduces surgical morbidity and mortality; therefore astute clinical observations and a thorough understanding of selected laboratory testing are imperative. Because of the risk of disease transmission associated with homologous blood transfusion, new alternatives in blood therapy--autologous blood from preoperative and perioperative salvage; the conservative and individualized use of homologous blood and its components; blood substitutes to support oxygen transport (e.g., modified hemoglobin solutions and perfluorochemical emulsions); new pharmacologic approaches for minimizing blood loss (e.g., desmopressin); and increasing the body's ability to produce blood (e.g., recombinant erythropoietin)--must be considered and the patient response carefully assessed. A broad knowledge base and clinical expertise are requisite in meeting the critical needs of the postoperative bleeding patient in a climate of rapidly developing diagnostic and therapeutic alternatives.